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Abstract
Immunomodulators have been used in recent years to reactivate host anti-tumor immunity in several hematological
malignancies. This report describes the effect of activating natural killer T (NKT) cells by a-Galactosylceramide (a-GalCer) in
the 5T33MM model of multiple myeloma (MM). NKT cells are T lymphocytes, co-expressing T and NK receptors, while
invariant NKT cells (iNKTs) also express a unique semi-invariant TCR a-chain. We followed iNKT numbers during the
development of the disease in both 5T33MM mice and MM patients and found that their numbers dropped dramatically at
the end stage of the disease, leading to a loss of total IFN-c secretion. We furthermore observed that a-GalCer treatment
significantly increased the survival of 5T33MM diseased mice. Taken together, our data demonstrate for the first time the
possibility of using a preclinical murine MM model to study the effects of a-GalCer and show promising results of a-GalCer
treatment in a low tumor burden setting.
Citation: Nur H, Fostier K, Aspeslagh S, Renmans W, Bertrand E, et al. (2013) Preclinical Evaluation of Invariant Natural Killer T Cells in the 5T33 Multiple Myeloma
Model. PLoS ONE 8(5): e65075. doi:10.1371/journal.pone.0065075
Editor: Kjetil Tasken, University of Oslo, Norway
Received November 14, 2012; Accepted April 21, 2013; Published May 31, 2013
Copyright:  2013 Nur et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was financially supported by the International Myeloma Foundation, Vlaams Liga tegen Kanker (VLK), FWO-Vl and the European Commission
Framework of the Erasmus Mundus External Cooperation Window under grant agreement 2009-1642/001-001-ECW. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Eline.Menu@vub.ac.be
. These authors contributed equally to this work.
Introduction
Natural killer T (NKT) cells are T lymphocytes that act as a
functional bridge between the innate and the acquired immunity;
therefore they have a crucial effect in tumor and pathogen
resistance as well as autoimmunity [1,2,3]. They co-express
conventional T cell (CD3) and NK cell (NK1.1) surface receptors,
and furthermore, an important subset of NKT cells called
invariant NKT cells (iNKTs) express a unique semi-invariant
TCR a-chain encoded by Va14.Ja18 in mice and Va24.Ja18 in
human [4]. These iNKTs can recognize glycolipid antigens
presented by the class I-like major histocompatibility complex
(MHC) molecule CD1d [5]. KRN7000 or a-Galactosylceramide
(a-GalCer) is a synthetic glycolipid which was first discovered in a
marine sponge [6,7] and which can be presented by antigen
presenting cells (APCs) such as professional dendritic cells (DCs)
through CD1d [8,9]. In this way DCs can induce activation of
iNKTs, leading to an anti-tumor Th1 (IFN-c) response or an
immunosuppressive Th2 (IL-4) response [10,11,12]. Multiple
myeloma (MM) is a B-cell malignancy hallmarked by uncontrolled
accumulation of terminally differentiated monoclonal plasma cells
in the bone marrow (BM) [12] which remains mostly incurable
despite all the currently available therapeutic strategies. Many
preliminary studies have shown critical roles of iNKTs in immune
responses against a variety of carcinogen-induced and genetic
tumor models when stimulated with a-GalCer [5,13,14,15]. Other
studies however indicated the development of iNKT anergy after
a-GalCer injection, possibly due to presentation by non-profes-
sional APCs which lack the proper co-stimulatory signals [4,14].
To overcome this problem, a-GalCer was loaded onto mature
DCs which resulted in a large expansion of iNKTs, leading to a
more prolonged response and induced more potent resistance to
tumor development [5,14,16]. Clinical studies in MM patients and
other patients with advanced cancer showed low biological
response (low IFN-c secretion) of iNKTs which was correlated
to a dysfunction of the cells [5,8,16,17,18]. It was namely found
that NKTs from cancer patients such as MM, isolated after in vivo
expansion, secreted less IFN-c after culture with 100 ng/mL a-
GalCer compared to NKTs from healthy donors [8]. Similarly,
Dhodapkar et al. demonstrated that in progressive MM, iNKTs
are still detectable in the blood and tumor microenvironment but
they have a profound deficiency in their IFN-c production while in
MGUS (monoclonal gammopathy of unknown significance)
patients, the deficiency was potentially reversible [16]. This defect
could be overcome in vitro as described above by using DCs
loaded with a-GalCer [14,16]. Importantly, when MM patients
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were injected with a-GalCer loaded DCs their circulating iNKT
pool expanded 100 fold and lasted for several months, which was
detectable by cell surface staining for TCR and a-GalCer-CD1d
dimer [8]. It was found that iNKTs can also mediate anti-
myeloma effects by cytotoxic lysis of MM cells and by activation of
NK cells and other antitumor T cells such as CD8+ T cells
[1,8,12]. This makes iNKTs interesting effectors against MM cells
not only by playing a role in controlling the malignant growth of
MM but also as a useful predictor of clinical outcome in MM
patients [1]. However, the development of effective iNKT-cell-
based immunotherapy is still a challenge and needs more
investigation [5]. Furthermore, the data on NKT activity in
MM patients is limited and the use of a-GalCer as a drug has not
been preclinically evaluated yet in MM. Therefore, in this study,
we investigated the activity and the characteristics of iNKTs in the
syngeneic preclinical 5T33MM murine model, an immunocom-
petent model which mimics the human disease closely. Findings in
this model could be translated into a clinical setting and thereby
contribute to the quick development of new therapeutic strategies
[19].
Materials and Methods
Patients
Patient samples have been collected with the approval of the
Ethics Board of UZ Brussel (BUN143201215265) and the
Tumourbank of Lille (CSTMT102). Samples are considered
‘‘waste samples’’ and therefore under Belgian legislation, informed
consent is not required. In short it is stated that in case of waste
samples for scientific research, the consent is assumed to be given
unless the patient specifically indicates otherwise. Patients at our
institution are aware of this right to refuse the use of the samples.
All patient samples were de-identified and analyzed anonymously.
Each patient received a number and we only had access to the
number.
5T33MM Mouse Model
C57Bl/KaLwRij mice were purchased from Harlan CPB
(Horst, the Netherlands). The mice were 6 to 8 weeks old when
used. They were housed and treated following the conditions
approved by the Ethical committee for animal experiments, VUB
(license no. LA1230281). Approval for these specific experiments
was obtained by the committee with approval number 09-281-5.
The animal ethics meet the standards required by the UKCCCR
Guidelines (UKCCCR, 1998). The 5T33MMvv model originated
spontaneously in C57BL/KaLwRij mice as described previously
[19,20] and have since been propagated by intravenous injection
of the diseased BM into young syngeneic recipients [21], which in
turn develop myeloma in 3-4 weeks. In short, mice were sacrificed
when showing signs of morbidity and the BM was flushed out of
the femurs and tibiae and crushed out of the vertebrae. The BM
cells were suspended in serum free medium (RPMI 1640 (Lonza,
Belgium), supplemented with penicillin-streptomycin, glutamine,
and MEM NEAA-pyruvate (Lonza)). The cells were then purified
by Lympholyte M (Cedarlane, Hornby, Canada) gradient
centrifugation at 1000 g for 20 min. The cell band on top of the
gradient contained enriched 5T33MM cells, with a purity
reaching 85%, as measured by flow cytometric analysis. Viability
was more than 95%. The model resembles the human disease
closely, with infiltration in the BM and secretion of paraprotein. As
the spleen is a hematopoietic organ in mice, infiltration also occurs
in spleen [22]. There is furthermore to a lesser extent tumor
growth in the extravascular compartment of the liver.
Flow Cytometry
For detection of murine iNKTs, cells were washed and
resuspended in PBS containing 1% BSA and 0.02% sodium
azide. Cells were incubated for 5 min at 4uC with FCR blocking
reagent (Miltenyi Biotic, Bergisch Gladbach, Germany), followed
by addition of anti-a-GalCer/CD1d tetramer-APC (Proimmune,
Oxford, UK), and anti-TCR-b-PE (clone H57-597, BD biosci-
ences, Erembodegem, Belgium) for 30 min at 4uC. 7-AAD (BD
biosciences) was added in the last 15 min, followed by washing and
resuspension in FACS buffer.
CD1d expression on 5T33MM+and – cells was assessed by
triple staining with anti-CD1d-PE (clone 1B1, BD biosciences),
anti-CD11b-FITC (clone M1/70, BD biosciences) and anti-
5T33MM idiotype [22] for 30 min at 4uC. For 5T33MM, anti-
IgG1-APC (clone X56, BD biosciences) was used as a second step.
5T33MM cells are considered 5T33MM+ and CD11b-. Appro-
priate isotype controls were used. All samples were acquired on a
FACS Canto and analysed with FACS Diva software (BD
biosciences).
For human iNKT analyses, an antibody mixture composed of
anti-CD3-FITC (clone sk7, BD biosciences)/anti-CD16CD56-PE
(clone 3G8, My31, Analis, Ghent, Belgium)/anti-CD45-Texas
Red (clone J33, Analis)/anti-CD19- PC5 (clone J3-119, Analis)
was used to determine the amount of T lymphocytes on peripheral
blood cells. In a second tube, anti-CD3-PC5 (clone ucht1, Analis),
anti-TCRVa24-FITC (clone 6B11, BD biosciences) and anti-
TCRVb11-PE (clone C21, Analis,) was used to gate iNKT cells.
Liver Perfusion and MACs-sorting
Mice were anesthetized i.p. with a 75 mg/kg ketamine (CEVA
Sante´ Animale, Libourne, France) –50 mg/kg medetomidine
hydrochloride (Virbac, Burgdorf, Germany) mixture and the
abdomen was opened immediately, renal veins were tied and the
inferior vena cava and portal veins were cannulated simulta-
neously with 18G needles. Livers were perfused with 25 mL of
10 mM EDTA/PBS (pH 7.4) at 7 mL/min within a closed
sterilised catheter system using a peristaltic pump (Gilson, France).
The flow-out was collected, washed and lysed with 2 mL Red
Blood Cell lysis buffer for 1 minute, and neutralized with RPMI-
1640 medium (Lonza), supplemented with 1% penicillin/strepto-
mycin and 10% FCS (Biochrome AG, Berlin, Germany) [23].
Purity of the liver iNKT cells was determined by flow cytometry
and mentioned in the results.
Spleen iNKT cells were crushed out of the spleen and purified
through MACS sorting using a-Galcer/CD1d tetramer-APC and
anti-APC microbeads (Miltenyi Biotec,) as previously described
[24]. Briefly, cells were labelled with the tetramer for 30 min on
ice and then the microbeads were added for 15 min. Cells were
passed over an LS column and the purity of the splenic iNKT cells
in the positive selection was determined by flow cytometry and
mentioned in the results.
Generation of Dendritic Cells and Co-culture with iNKTs
Murine BM progenitor cells were isolated by flushing the
content of the femur and tibia of naive mice with sterile PBS as
described previously [25]. DCs were cultured from these BM
progenitor cells and plated in 100620 mm cell culture dishes
(Greiner Bio-One, GmbH, Germany) at 16106/2 mL in supple-
mented RPMI-1640 media with 5% FetalClone I (FCI, Hyclone,
Logan, USA). 20 ng/mL of recombinant mouse granulocyte
macrophage colony stimulating factor (GM-CSF, R&D systems,
Oxon, UK) and 50 mM b-mercaptoethanol (b-ME, Sigma-
Aldrich, Belgium) were added to the culture at day 0. On day 3,
50% of the volume fresh medium with GM-CSF and b-ME was
iNKT Cells in Multiple Myeloma
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added. On day 6, 50% of the media were completely refreshed.
On day 7, the immature DCs were harvested and lipopolysac-
charide (LPS, 100 ng/mL, Sigma-Aldrich) was used to mature
DCs overnight in the presence of 100 ng/mL alpha-galactosylcer-
amide (a-GalCer) or vehicle (0.5% Tween-20 in PBS). a-GalCer,
dissolved in DMSO at 1 mg/mL was kindly provided by Dr. S
Van Calenbergh (University of Ghent, Belgium) and kept at
220uC. On day 8, after extensive washing, a-GalCer loaded/
unloaded DCs (26105/well) were co-cultured with iNKTs
(56104/well) in supplemented RPMI-1640 medium with 10%
FCS at 4:1 ratio and incubated for 72h at 37uC and 5% CO2.
Cytokine Levels
Supernatant from in vitro co-cultures was collected to deter-
mine mouse IFN-c (eBioscience, Vienna, Austria) and IL-4 (R&D
systems, Oxon, UK) concentrations by ELISA according to the
manufacturer’s instructions. Cytokine level was also determined in
serum collected from mice during the time course of the disease
after intraperitoneal (i.p.) administration of 2 mg a-GalCer.
Real-time Quantitative PCR (RT-PCR)
Total RNA from 36106 NKT cells was extracted by using the
RNeasy kit (Qiagen, the Nederlands). Total RNA was reverse
transcribed using the Verso cDNA synthesis kit (Thermo
Scientific, CO, USA), according to the manufacturer’s instruc-
tions. RT-PCR was performed using MaximaH SYBR Green/
ROX qPCR Master Mix (Fermentas, Germany) on an ABI Prism
7900 Fast instrument using gene-specific primers. The primer
sequences for Va14 were as follows: forward primer: 59- AGG
TAT GAC AAT CAG CTG AGT CCC -39 and reverse primer:
59- CTA AGC ACA GCA CGC TGC ACA -39. The PCR cycles
consisted of an initial denaturation step at 50uC for 2 min and
95uC for 10 min followed by 40 cycles at 95uC for 15 s and 60uC
for 1 min. Each sample was amplified in triplicate. The relative
standard curve method was used to quantify the relative Va14
expression in the 5T33MM cells and abl was the reference gene.
Relative standard curves (25, 5, 1, 0.2 ng) were prepared using
cDNA from 5T33MM control samples.
Statistics
Mann-Whitney and student’s t test were used for statistical
analyses and Kaplan-Meier analysis was used for the survival
assay. p,0.05 was considered significant.
Results
The Evolvment of iNKT Numbers in MM
We first investigated the frequency of iNKTs in the blood, BM,
spleen and liver of both healthy and terminally diseased 5T33MM
mice by co-staining the cells with anti-TCR-b and CD1d tetramer.
A representative staining is shown in Figure 1A. Taking the
average of 6 mice (figure 1B), the highest percentage of iNKTs was
found in the liver (naive 7.6%61.64) with a significant decrease in
5T33MM mice (2.1%60.73). The percentage was also signifi-
cantly decreased in spleen from 1.1%60.48 in naive to
0.6%60.18 in 5T33MM mice, while in BM we saw a significant
upregulation of iNKT number from 0.18%60.13 to 0.43%60.16
and no significant differences in the blood. The upregulation in the
BM could suggest tumor surveillance by the iNKTs. Human
iNKT number was also determined in blood samples of 55 MM
patients (29 at diagnosis and 26 at relapse) and 28 patients with
Monoclonal Gammopathy of Unknown Significance (MGUS). We
saw a median of 670 iNKT/mL in the 62 healthy donors and this
number gradually decreased to 248, and 178 in MGUS and newly
diagnosed patients. There was a significant decrease to 74 iNKT/
mL in relapsed patients (Figure 2). As we wished to determine the
moment when iNKT numbers dropped, we followed the
frequency of iNKTs in the liver and spleen of MM mice during
the development of the disease. We analyzed the number of
iNKTs in the first, second, third and terminal week of the disease.
Liver [23] and MACS-enriched spleen [24] cells were stained with
a-GalCer/CD1d tetramer (Figure 3A, upper panel). We found
40%69.15 MACS-enriched spleen cells in healthy mice and this
number gradually dropped to 8%61.2 at the third week of
disease. This coincided with a sharp increase in tumor load from
10%65.29 at week 2 to 51%68.71 at week 3, suggesting a
correlation. Similar results were found with the liver iNKT cells
which dropped from 7.6%61.5 to 4.7%60.47 at week 3. There
was a significant decrease in both liver and spleen iNKT number
when comparing naive and end stage diseased animals (Figure 3A,
lower panel, n = 6). These findings relate to what we saw in
patients, namely a sharp decline in iNKT number at the
advanced/relapsed stage of MM disease.
IFN-c Secretion in MM
To analyze the activity of iNKTs in vitro and to determine if
lower iNKT number results in lower cytokine secretion, total liver
iNKTs from different time points of the disease (Figure 3B, upper
panel) were co-cultured with naive matured bone marrow-derived
DCs in the presence or absence of 100 ng/mL a-GalCer. Liver
iNKTs are more active compared to spleen iNKTs (data not
shown) [1,4]. Naive iNKTs could secrete up to 2.360.71 ng/mL
IFN-c when stimulated with a-GalCer, and this level increased
with the progression of MM to reach 3.360.017 ng/mL at week
2. However, the IFN-c secretion of the iNKTs dropped to
undetectable levels upon further progression of the disease (week
4). This drop was significant (Figure 3B, lower panel, n = 6).
Similar results were obtained using DCs derived from BM of
5T33MM mice, implying no defect in the DCs (data not shown).
Unstimulated iNKTs secreted a background level of up to
3006251 pg/mL IFN-c during the course of the disease. These
data indicate that a drop in cytokine secretion from the iNKTs
could be preceded by a decline in iNKT number. To confirm that
this is an actual decline in iNKT number and not the result of
internalization of the Va14 receptors, we performed RT-PCR of
the Va14 receptor of healthy and terminally diseased murine liver
iNKTs (Figure 3C). If the receptor would be internalized, mRNA
levels would still be high. One of the 5T33MM samples was used
as reference and the other values were calculated relative to this.
We could find that the mRNA expression of Va14 correlated to
the number of iNKTs measured by FACS with a clear drop in
iNKT number in terminally diseased 5T33MM mice. Only very
slight IL-4 production (662 pg/mL) was observed when a-GalCer
was administered to the culture (data not shown) indicating that
liver iNKTs are skewed to a Th1 profile and can therefore be used
as an immunotherapeutic tool in MM when activated by adjuvants
such as a-GalCer.
CD1d Expression
It has been described previously that the expression of CD1d
molecules is significantly downregulated in patients with advanced
stages of MM compared to healthy controls, MGUS and early
myeloma patients, suggesting a reason for loss of iNKT activity
[26]. To investigate if this is similar in the 5T33MM model, we
followed the expression of the CD1d molecules on total spleen and
BM cells during the course of the disease (Figure 3D, upper panel).
Results showed a small downregulation of CD1d expression on
spleen cells starting from week 2. Approximately, 93%62.1 CD1d
iNKT Cells in Multiple Myeloma
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Figure 1. iNKT numbers in the 5T33MMmodel. (A) Representative FACS analysis of murine iNKT cells from blood, BM, spleen and liver in naive
and 5T33MM mice. Live cells (7-AAD negative) were stained with a-GalCer/CD1d tetramer which specifically binds to Va14 of the invariant TCR and
with TCR-b. Double positive iNKT cells were gated. The percentages are indicated in each plot. (B) Box plots of the distribution of iNKT number data,
obtained from 6 mice from independent experiments. Differences between naive and 5T33MM cells in BM, liver and spleen are significant (* and **
indicate p,0.05 and p,0.005, Mann-Whitney test).
doi:10.1371/journal.pone.0065075.g001
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expression was seen in naive spleen cells while the level decreased
with the progression of the disease to 82%63.9 in week 2,
74%61.6 in week 3 and 68%69.3 at end stage. The reduction at
end stage was significant (Figure 3D, lower panel, n = 6) In naive
mice, CD1d was less expressed on BM cells compared to spleen
cells (52%62.1) and in tumor bearing mice, the expression
declined in week 1 and week 2 (35%67.2 and 43%61.6
respectively) but did not decline further at the terminal point.
Furthermore we analyzed CD1d expression on the MM cells
themselves and found that the receptor was highly expressed
(79%66.2 in spleen and 67.7%62.3 in BM) in week 1 and that
this did not alter during the course of the disease (82.8%64.1 in
spleen and 75%67.5 in BM) at end stage (data not shown).
In vivo Response to a-GalCer
As we wished to investigate whether the kinetics of the in vivo
response of iNKTs to a-GalCer altered during the course of the
disease, we injected naive, non-terminal and terminal diseased
5T33MM mice with a-GalCer. Cytokine secretion in the
peripheral blood was followed at different time points after
injection (Figure 4A). It has been described that an IL-4 peak
appears faster than an IFN-c peak [5,14]. In the 5T33MM model,
the serum level of IFN-c peaked at 18h in naive and non-terminal
diseased mice and returned to baseline by 48h, however, the
response of IFN-c in diseased mice was twice (600064925 pg/
mL) that measured in naive mice, confirming the possibility of
inducing Th1 responses with a-GalCer in vivo in healthy and
diseased mice. These findings are consistent to previous results
obtained in different mouse tumor models [14,27]. No response
could however be detected from terminally diseased mice. IL-4
was detected only in naive mice after 2h of a-GalCer adminis-
tration (6006489 pg/mL) and completely disappeared at 18h
(data not shown). We finally evaluated the effect of a-GalCer on
the survival of MM mice. When mice were injected i.p. with a-
GalCer on the same day of 5T33MM inoculation, we saw no
significant survival increase compared to vehicle. Vehicle mice had
an average survival of 30 days while a-GalCer injected mice 32
days (data not shown). However, the survival was significantly
increased when mice were injected with a-GalCer loaded DCs on
the same day of 5T33MM inoculation (29 days survival) compared
to mice injected with unloaded DCs (22 days survival, Figure 4B),
indicating that DC presentation of a-GalCer is necessary to have
an anti-tumoral effect.
Discussion
Natural killer T (NKT) cells can be activated by the synthetic
glycolipid a-GalCer and this has been shown to lead to anti-tumor
responses in different mouse models such as the transgenic Em-myc
B cell lymphoma and AML-ETO9a leukemia mouse model [28].
In MM however, not much is known about the preclinical
possibilities of harnessing NKT cells due to the lack of appropriate
mouse models. In this article we demonstrate the ability to use the
immunocompetent 5TMM model as a murine model to study the
effects of a-GalCer on iNKTs. First we wished to analyze the
presence of iNKTs in healthy and MM diseased mice and to
determine whether this correlated to patient data. We found a
significant drop in liver and spleen iNKT number, while we also
saw a small but significant upregulation of iNKTs in the BM,
indicating that a part of the iNKTs migrated to the tumor. The
general reduction in iNKTs correlated to a reduction in circulating
iNKT we observed when comparing healthy donors to MM
patients with relapsed disease. We furthermore saw that this
decrease was gradual, with already a reduction in MGUS patients,
a further reduction in newly diagnosed MM patients but with a
most pronounced decline in patients with relapsed disease. This
has also been found by others who described that in MM patients,
the progression of the disease is associated with loss of IFN-c
secreting iNKTs [16,28]. We next wished to determine when the
drop in iNKT number actually occurred in the 5T33MM model
so we performed time course experiments. We found that there
was a sharp decrease at week 3 of the disease which coincided with
a sharp increase of tumor load. Loss of iNKT cells was
furthermore confirmed by RT-PCR for the Va14 receptor. This
is the invariant chain of the TCR receptor, associated with iNKTs.
A reduction of this receptor in the total cell population indicates a
reduction in NKT cell number. We next investigated whether this
decline in iNKT number lead to a decrease in total IFN-c
secretion in vitro. When we co-cultured iNKTs of different disease
stages with a-GalCer loaded DCs, we saw indeed a reduction in
IFN-c secretion at week 4. Interestingly, at week 3, IFN-c
expression is still high, indicating that the loss of IFN-c production
comes later than the drop in iNKT numbers. A possible reason for
loss of iNKT activity in cancer patients has been given by van der
Vliet et al [29] who found in melanoma and renal cell cancer
patients that the circulating myeloid dendritic cells have an altered
cytokine profile which leads to a loss of Th1 activity in the
remaining iNKT cells. We compared the possibility of BM derived
DCs from healthy and diseased mice to activate iNKTs, but found
no difference. It has also been previously described [26] that loss of
CD1d, the lipid presenting molecule, could be the reason for the
loss in iNKT activity, therefore we followed its expression during
the course of the disease, both on total spleen and BM cells,
Figure 2. iNKT numbers in MM patients. Human iNKT (number/
mL) were analyzed in blood samples of 51 Patients (mean age is 64
years old) and 62 healthy donors (mean age is 66 years old) by flow
cytometry. Total number of iNKT cells were calculated by determining
the % iNKT cells (CD3, TCRVa24 and TCRVb11+ cells) on total T
lymphocyte number (* and ** indicate p,0.05 and p,0.01, Student t-
test, ns = not significant).
doi:10.1371/journal.pone.0065075.g002
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Figure 3. iNKT frequency and activity during the development of the disease in the 5T33MM model. (A, upper panel) Frequency of
iNKTs in liver and spleen during the course of the disease, analyzed by flow cytometry as was done in figure 1A. Mice were isolated at different time
points and liver and MACS-sorted splenic iNKTs were stained with a-GalCer/CD1d tetramer. Plasmacytosis (tumor load) was assessed on May-
Gru¨nwald Giemsa stained cytosmears of the isolated BM. The mean 6 SD of 3 mice in independent experiment is shown. (A, lower panel) The
mean % iNKT cells in liver and spleen of naive and end stage 5T33 mice (n = 6, ** indicates p,0.01, Mann-Whitney test). (B, upper panel) In vitro
iNKT activity. Mice were isolated at different time points and liver iNKTs were co-cultured with a-GalCer loaded or unloaded DCs for 72 h. IFN-c
secretion in the co-culture was measured by ELISA. The mean6 SD of 3 mice in independent experiment is shown. (B, lower panel) The mean IFN-c
secretion of DC co-cultures with liver iNKT cells of naı¨ve and end stage 5T33 mice (n = 6, ** indicates p,0.01, Mann-Whitney test). (C) Gene expression
iNKT Cells in Multiple Myeloma
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containing the APCs and also on the 5T33MM cells as it has been
described that MM cells can function as APCs themselves [28].
We saw a small but significant decline in CD1d expression in
spleen cells but not in BM cells, indicating that this is not the major
reason for loss of IFN-c secretion. 5T33MM cells expressed high
levels of CD1d that did not alter during the course of the disease.
This is in contrast with Spanoudakis et al [26] who found that
CD1d was significantly downregulated in advanced stages of MM
and myeloma cell lines. We performed co-culture experiments in
which 5T33MM cells were used as APCs to trigger cytokine
secretion by healthy iNKTs but we found no activation (data not
shown). This is in contrast to a study which demonstrated the
possibility of injecting irradiated tumor cells loaded with a-GalCer
in the Vk*myc MM model which led to a reduction in tumor load
if injected before inoculation with tumor cells [28]. The 5T33MM
cells seem to be missing the necessary co-stimulatory molecules
such as CD40, CD70, CD80, CD86 and OX40L [11,30,31,32], as
they only expressed 5% CD40, 8% CD80 and 2% CD86 on their
membrane (data not shown) in contrast to normal APCs to elicit a
response. Another possibility is that the 5T33MM cells display a
non functional form of CD1d, missing the full cytoplasmic tail
which is necessary for activity [33]. Further investigation is
necessary to examine this CD1d deficiency. We finally examined
the possibility of inducing an anti-tumor response in vivo by
injecting a-GalCer. It has been shown in vivo that inducing a Th1
response in iNKTs leads to the recruitment of other immune cells
against the tumor [34]. We first looked at the in vivo response of
iNKTs to a-GalCer by measuring IFN-c secretion in the
peripheral blood of the mice. Treating week 2 diseased mice
resulted in a robust cytokine response in vivo; similar to that of
naive mice, but when treating end-stage diseased mice this activity
was lost, confirming the cytokine loss we saw in vitro. As it has
been shown that a-GalCer can fail to elicit a clear Th1 or Th2
response in iNKTs, several analogues of a-GalCer have been
discovered and modified to improve either the Th1 or Th2
response [35]. OCH has been shown to give a stronger Th2
response, suitable for auto-immune diseases [11,36]; both the
carbon glycosidic analogue (a-C-GalCer) and naphthylurea 60-
derived a-GalCer (NU- a-GalCer) have been shown to be superior
Th1 polarizers in B16 melanoma cells [37,38,39]. The group of
Tyznik demonstrated that plakoside-based antigens were also able
to stimulate mouse and human iNKTs and cause a prolonged
systemic synthesis of IFN-c. [40]. Studies of these new derivatives
in MM are however lacking and should be further explored. We
finally performed a Kaplan-Meyer survival analysis in which we
treated 5T33MM inoculated mice with either vehicle loaded DCs
or a-GalCer loaded DCs. We found that a-GalCer treatment
significantly prolonged mouse survival from 22 days to 29 days.
This opens the road to possibilities of combination therapy in
which the tumor is targeted with a known cytotoxic drug and the
residual disease is targeted by iNKT activation. Recently, a clinical
trial using a-GalCer loaded DCs combined with the immuno-
modulatory drug Lenalidomide led not only to the activation of
NKT cells but also to the activation of the other downstream
components of the innate immunity including NK cells, monocytes
and eosinophils which can collectively induce tumor regression in
MM. [41].
Taken together, our data demonstrate for the first time the
possibility of using a murine model as a preclinical MM model to
study the effects of a-GalCer on iNKTs. This study also opens up
the possibility of using the 5T33MM model to evaluate other
immunotherapeutics in MM such as DC vaccinations. As our data
show that there is an iNKT impairment at the end stage of the
disease, future studies should focus on overcoming this impairment
of the Va14 receptor of liver iNKTs of healthy and diseased 5T33MM was assessed by RT-PCR (n = 6). (D, upper panel) Expression of CD1d in live
spleen and BM cells in the 5T33MM model during the course of the MM disease compared to tumor load. Mice were isolated at different time points
of the disease and spleen and BM cells were double stained for CD1d and 5T33MM. The mean 6 SD of 3 mice in independent experiment is shown.
(D, lower panel) The mean CD1d expression in spleen and BM cells of naive and end stage 5T33 mice (n = 6, ** indicates p,0.01, Mann-Whitney
test).
doi:10.1371/journal.pone.0065075.g003
Figure 4. iNKT activity in vivo. (A) In vivo cytokine secretion after i.p. administration of 2 mg a-GalCer in 200 ml of PBS to healthy, non-terminal
and terminal sick 5T33MM mice. Serum was collected during a time course, responses were followed by determining IFN-c and IL-4 levels by ELISA
(mean 6 SD is shown from 5 mice in each group). (B) Kaplan-Meier survival assay. Mice were intravenously injected with a single dose of matured
DCs (66105 cell/mouse) loaded with a-GalCer (100 ng/mL) or unloaded at the same day of inoculation with 5T33MM cells (n = 8 mice/group,
p = 0.0366). Vehicle mice had an average survival of 22 days, a-GalCer treated mice 29 days.
doi:10.1371/journal.pone.0065075.g004
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by combining a-GalCer or its newly Th1 polarizing analogues
[27] with immunomodulatory agents. Combination studies with
known cytotoxic drugs could give novel insights into how the MM
tumor can be targeted by multiple pathways, leading ultimately to
improved treatment of MM patients.
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